BioPharma Resources

Drug Trial Radar · NCT04634409

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)

Last checked: Nov 19, 2026Latest source record: Jul 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,755 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,755

Actual

Start

Oct 29, 2020

Primary completion

Jul 27, 2021

Study completion Oct 18, 2021

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
AbCellera Biologics Inc.; Shanghai Junshi Bioscience Co., Ltd.; GlaxoSmithKline; Vir Biotechnology, Inc.
First posted
Nov 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.

Conditions

  • COVID-19

Interventions

  • BamlanivimabDrug

    Administered IV.

  • EtesevimabDrug

    Administered IV.

  • PlaceboDrug

    Administered IV.

  • VIR-7831Drug

    Administered IV.

  • BebtelovimabDrug

    Administered IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Greater Than 5.27Time frame: Day 7
  2. Treatment 7-8, Amendments (C-e): Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27Time frame: Day 7
  3. Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27Time frame: Day 7

Locations

141 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • The Institute for Liver Health

    Mesa, Arizona

  • Perseverance Research Center

    Scottsdale, Arizona

  • CRI of Arizona, LLC

    Sun City West, Arizona

  • Fiel Family and Sports Medicine PC

    Tempe, Arizona

  • The Institute for Liver Health

    Tucson, Arizona

  • KLR Business Group, Inc. dba Arkansas Clinical Research

    Little Rock, Arkansas

  • Applied Rsch Ctr - Arkansas Inc.

    Little Rock, Arkansas

  • Smart Cures Clin Research

    Anaheim, California

  • Hope Clinical Research

    Canoga Park, California

  • VCT-Covina

    Covina, California

  • Neighborhood Healthcare

    Escondido, California

  • Chemidox Clinical Trials

    Lancaster, California

  • Ark Clinical Research

    Long Beach, California

  • Long Beach Clinical Trials LLC

    Long Beach, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Central Valley Research, LLC

    Modesto, California

  • Inland Empire Liver Foundation

    Rialto, California

  • Sutter Institute For Medical Research

    Sacramento, California

  • Wolverine Clinical Trials, LLC

    Santa Ana, California

  • St. Joe Heritage HC-Santa Rosa

    Santa Rosa, California

  • Stanford University Hospital

    Stanford, California

  • Mazur, Statner, Dutta, Nathan

    Thousand Oaks, California

  • South Bay Clinical Research Institute

    Torrance, California

  • Infect Disease Doctors Med Grp

    Walnut Creek, California

  • Allianz Research Institute

    Westminster, California

  • Future Innovative Treatments LLC

    Colorado Springs, Colorado

  • Georgetown Univ Sch of Med

    Washington D.C., District of Columbia

  • Synergy Healthcare LLC

    Bradenton, Florida

  • Holy Cross Hospital Inc.

    Fort Lauderdale, Florida

  • I R & Health Center, Inc.

    Hialeah, Florida

  • Encore Medical Research

    Hollywood, Florida

  • Elixia CRC

    Hollywood, Florida

  • Lakeland Regional Medical Center

    Lakeland, Florida

  • Hope Clinical Trials, Inc.

    Miami, Florida

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida

  • Bio-Medical Research, LLC

    Miami, Florida

  • Clinical Site Partners, LLC d/b/a CSP Miami

    Miami, Florida

  • Panax Clinical Research

    Miami Lakes, Florida

  • Testing Matters Lab

    Sunrise, Florida

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.